Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Cash from Investing Activities (2017 - 2025)

Sutro Biopharma's Cash from Investing Activities history spans 9 years, with the latest figure at $40.0 million for Q3 2025.

  • For Q3 2025, Cash from Investing Activities fell 72.85% year-over-year to $40.0 million; the TTM value through Sep 2025 reached $113.8 million, up 5.85%, while the annual FY2024 figure was $218.5 million, 5668.5% up from the prior year.
  • Cash from Investing Activities for Q3 2025 was $40.0 million at Sutro Biopharma, up from $2.6 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $147.3 million in Q3 2024 and bottomed at -$121.7 million in Q1 2021.
  • The 5-year median for Cash from Investing Activities is $5.9 million (2021), against an average of $5.7 million.
  • The largest YoY upside for Cash from Investing Activities was 715.44% in 2022 against a maximum downside of 3380.69% in 2022.
  • A 5-year view of Cash from Investing Activities shows it stood at $20.8 million in 2021, then crashed by 282.29% to -$37.9 million in 2022, then soared by 37.93% to -$23.5 million in 2023, then soared by 472.08% to $87.5 million in 2024, then crashed by 54.29% to $40.0 million in 2025.
  • Per Business Quant, the three most recent readings for STRO's Cash from Investing Activities are $40.0 million (Q3 2025), $2.6 million (Q2 2025), and -$16.3 million (Q1 2025).